Deepflare

Deepflare is an AI-powered biotechnology company that specializes in in silico immunogenicity prediction and de novo antigen design. The company has developed a proprietary platform that moves beyond traditional binding affinity metrics to predict T-cell immunogenicity, integrating advanced machine learning algorithms with computational biology tools such as RFdiffusion. This seamless workflow allows researchers to transition from target protein sequences to optimized, bench-ready antigen candidates within 24 hours. The platform enables users to iteratively apply custom feedback, such as modifying immunogenicity, solubility, or specific structural regions, to develop superior candidates for vaccines and biotherapeutics.

This technology is designed to help biotech companies de-risk their discovery pipelines and accelerate the development of more effective therapies. By addressing the validation crisis in antigen design, where models often perform well in silico but fail in experimental settings, Deepflare provides a solution that has been validated in prospective in vitro and in vivo studies. The platform has demonstrated significantly higher precision compared to state-of-the-art models across various viral and cancer targets, assisting partners in achieving better hit rates and improved immune responses in their vaccine development efforts. Key offerings include an interactive design tool, epitope discovery modules, and comprehensive manufacturability assessments.